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Abstract: Strongyloidiasis is an infection caused by the helminth, Strongyloides stercoralis. Up to
370 million people are infected with the parasite globally, and it has remained endemic in the
Indigenous Australian population for many decades. Strongyloidiasis has been also reported in other
Australian populations. Ignorance of this disease has caused unnecessary costs to the government
health system, and been detrimental to the Australian people’s health. This manuscript addresses the
12 criteria required for a disease to be included in the Australian National Notifiable Disease List
(NNDL) under the National Health Security Act 2007 (Commonwealth). There are six main arguments
that provide compelling justification for strongyloidiasis to be made nationally notifiable and added
to the Australian NNDL. These are: The disease is important to Indigenous health, and closing
the health inequity gap between Indigenous and non-Indigenous Australians is a priority; a public
health response is required to detect cases of strongyloidiasis and to establish the true incidence
and prevalence of the disease; there is no alternative national surveillance system to gather data on
the disease; there are preventive measures with high efficacy and low side effects; data collection is
feasible as cases are definable by microscopy, PCR, or serological diagnostics; and achievement of the
Sustainable Development Goal (SDG) # 6 on clean water and sanitation.
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1. Introduction
Strongyloidiasis is an infection caused by the intestinal and tissue helminth, Strongyloides
stercoralis [1]. S. stercoralis has been estimated to infect up to 370 million people worldwide [2].
In Australia, strongyloidiasis remains endemic in Indigenous populations, infecting communities in
Queensland [3], the Northern Territory [4–9], Western Australia [10], northern South Australia [11],
and northern New South Wales [12]. Seroprevalence in some communities reaches 60% [4–9,13].
Despite the prevalence and potential for morbidity and mortality posed by this disease, the true
incidence in Australia remains unknown [2] as a consequence of both under-diagnosis of the disease
and the absence of mechanisms to capture surveillance data [14]. The absence of reliable national data
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of the geographic extent and rate of transmission of this disease blinds medical and public health
professionals attempting to institute effective control. This knowledge gap is not unique to Australia.
Schar et al. (2013) noted that adequate information on S. stercoralis prevalence is still lacking from
many countries, but their review found that the information that does exist points out to it being an
infection that must not be neglected. They recommended information needs to be collected in a range
of socio-economic and ecological settings and that in many settings the integration of control and
treatment of S. stercoralis into a holistic helminth control program is warranted [15].
S. stercoralis is a soil-transmitted helminth, infecting a human when infective stage larvae penetrate
the skin, enter the circulation, and subsequently travel to the lungs via the blood, from where it
is swallowed into the gut [16]. This is the traditional ordered pathway, though evidence exists
that random migration through the body to reach the intestine is also likely, even in primary
infection [17–19]. A free-living phase of the parasitic life cycle occurs in the soil after host defaecation in
the open, but this can only last one generation, and thus a soil reservoir of the parasite is not a factor in
long-term control after implementation. Symptoms are protean, including respiratory, gastrointestinal,
and skin disorders [18,20]. Unlike most other soil-transmitted helminth infections, S. stercoralis
larvae can persist indefinitely inside the host through asexual reproduction by parthenogenesis and
subsequent autoinfection [21,22].
After initial infection, there is a rapid increase in numbers as the result of an autoinfective
burst [23]. This causes acute disease. This typically abates in immunocompetent people, becoming
asymptomatic, or mildly symptomatic, often mimicking the symptoms of other diseases [9,24]. Due to
its peculiar autoinfective nature, disease is often lifelong and a single remaining larva of S. stercoralis
post-treatment can cause recrudescence of disease. In immunocompetent persons, the disease is
chronic and long-lasting. In immunocompromised/immunosuppressed persons, or those receiving
corticosteroid treatment, the infection may transform to a hyperinfective or disseminated disease
syndrome, with up to 90% mortality [16,25–29].
Strongyloides is typically found in tropical and subtropical zones, but is mainly associated with
areas of low socioeconomic status as a consequence of inadequate sanitary conditions [30]. This is
supported by evidence of strongyloidiasis being found in desert communities [6,11]. Strongyloidiasis
is described as the most neglected of the Neglected Tropical Diseases (NTDs) [14], and it is important
to make strongyloidiasis notifiable so that epidemiological and prevalence data can be obtained to
inform appropriate strategies for controlling the disease.
2. The Australian National Notifiable Disease Surveillance System (NNDSS)
The Quarantine Act (NSW) of 1832 was the first legislative document to cover public health
issues and included mandatory reporting of diseases to local health authorities in Australia [31].
The Communicable Disease Network Australia (CDNA) was established in 1989 to enhance
national communicable disease surveillance reporting to the then National Public Health Partnership
(NPHP) [32]. In 2006, NPHP split into the Australian Health Protection Committee (AHPC) and the
Australian Health Development Committee (AHDC). CDNA now operates under the AHPC.
The Australian National Notifiable Diseases Surveillance System (NNDSS) was first introduced
in 1990 and serves as a platform to collate and report data on nationally-approved notifiable diseases
from all jurisdictions to the Commonwealth [32,33]. The National Notifiable Disease List (NNDL)
was created in 2008 under the National Health Security Act 2007 (Commonwealth), a document that
contains a list of notifiable communicable diseases to the NNDSS.
3. Criteria for Inclusion on the National Notifiable Disease List
To determine whether a disease should be notifiable, there are currently 12 criteria against which
a disease is ranked. These criteria were established by the CDNA in 2014 [32]. Table 1 presents an
assessment of strongyloidiasis against each of these criteria. A score of 28 (if conservative estimates
are used) to 30 (if less conservative estimates are used) was calculated for strongyloidiasis based on
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CDNA descriptors. The CDNA criteria state that if a disease scores less than 15, national notification
is not recommended; if it falls between 15 to 25, national notification is to be considered further;
and if it is higher than 25, national notification is recommended. As such, even with a conservative
estimate of 28, strongyloidiasis fulfils the requirements for national notification to be recommended [32].
The criteria can be found at: (http://www.health.gov.au/internet/main/publishing.nsf/Content/
8DF6148BCAC589D6CA257EE5001D0DF7/$File/Protocol-change-NNDL.pdf).
Based on Table 1 there are six key arguments for making strongyloidiasis notifiable:
• The disease is important to Indigenous health, and closing the health inequity gap between
Indigenous and non-Indigenous Australians is a priority.
• A public health response is required to detect cases of strongyloidiasis and to establish the true
incidence and prevalence of the disease.
• There is no alternative national surveillance system to gather data on the disease.
• There are preventive measures with high efficacy and low side effects.
• Data collection is feasible as cases are definable by microscopy, PCR, or serological diagnostics.
• Achievement of the Sustainable Development Goal (SDG) # 6 on clean water and sanitation.
4. Prevalence of Strongyloidiasis in Australia
Strongyloidiasis may have been present in Australia prior to the arrival of Europeans. Due to
improvements in sanitation and healthcare, it is no longer typically seen in non-Indigenous Australian
communities [34], but remains a major health problem for Indigenous communities, particularly in
remote areas. Despite its long-term persistence in Australia, it is difficult to determine the true
distribution and prevalence of the disease. The first confirmed reports of strongyloidiasis in
Australia date back to the early 1900s in north Queensland [35–37]. The first reports of it specifically
affecting Aboriginal communities (in Atherton Tablelands) date back to the early 1900s, at which
time it was noted to affect Aboriginal people at almost 30 times that of non-Aboriginal [34].
To date, infection-related mortality rate in Indigenous people is much higher compared with that in
non-Indigenous population. Strongyloidiasis is one of the causes of deaths [38]. Current estimates
of strongyloidiasis incidence are limited and based on opportunistic testing in hotspot areas and
diagnostic pathology laboratory data [39]. The former is biased towards high prevalence communities
and the latter towards subjects with easy access to healthcare and laboratory services and having
sufficiently symptomatic disease to require diagnostic evaluation. There is also no standard detection
method available. A study conducted in north Queensland in 2006 showed a strongyloidiasis
prevalence in Indigenous and non-Indigenous populations of 24% and 10% respectively [40].
An epidemiological study with Aboriginal communities in Northern Australia conducted over
2010–2011 showed a strongyloidiasis seroprevalence of 21% [7]. Overall, based on studies completed
in different localized endemic areas from 1980 to 2010, strongyloidiasis prevalence is estimated to
range from 2% to 41% based on faecal microscopy surveys [3,5,10,41] and from 5% to 60% based on
serology survey tests [42,43]. Furthermore, infected people are known to live elsewhere in Australia
apart from endemic areas [44].
Strongyloidiasis also affects other populations. GeoSentinel Surveillance Network site holds
a database for returned international travelers with infectious gastrointestinal disease. Based on
analysis of their international database during the period 1996–2005, S. stercoralis was rated the
fifth most common pathogen [45]. Screening and treatment is now policy for refugees coming to
Australia. However, screening has not yet been introduced to policy or systems for endemic Aboriginal
communities in Australia. Immigrants and refugees from South East Asia also have high prevalence
rates, as do returned travelers [20,46]. In a South Australian study, 11.6% of Vietnam veterans tested
seropositive for S. stercoralis [47]. Four non-Indigenous cases of strongyloidiasis acquired through
occupational exposure were reported in Central Australia [44].
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Table 1. Strongyloides stercoralis against 12 criteria for NNDL assessment.
# Criterion Score Notes on Strongyloidiasis
Priority setting
1 Necessity for publichealth response
2/4 = case reporting important for
detecting outbreaks that require
investigating or contacts require
routine intervention
A public health response and immediate intervention is required based on the following:
1. Inadequate hygiene and sanitary conditions are the main factors for human strongyloidiasis.
A person can get infected when coming into contact with or near infected human or dog faeces.
In low socioeconomic status communities, such as some Indigenous communities,
sanitation conditions present a high risk for strongyloidiasis transmission, contamination,
re-infection, and recurrence [30]. Therefore, it is crucial to get a public health response to create
and maintain adequate sanitary and hygiene conditions in the communities to prevent the
disease. Culturally comprehensive health education for understanding the nature of infectious
diseases and how they are transmitted is fundamental for maintaining hygienic conditions [48].
2. There is the opportunity to highlight environmental health role in the public health response.
There is an opportunity to make a difference in endemic communities and specific
families/communities with high need targeting the SDG # 6 on clean water and sanitation.
3. Interventions programs such as targeted mass drug administration (MDA) have shown to be
very effective in reducing the reservoir of human infection, and need to be implemented
regularly on a local and national level in endemic communities [7].
4. Another intervention program in an endemic Indigenous community incorporated
S. stercoralis screening into the adult health check, and positive cases were treated and followed
up. This selective chemotherapy intervention resulted in a decreased risk of potentially fatal
hyperinfection and decreased prevalence in the community [13,49].
5. Strongyloidiasis has been shown to prevent weight gain in children, and therefore it is critical
to identify and treat S. stercoralis infection to avoid intervention by social services.
This intervention can result in child removal from parents into care if the child shows signs of
malnutrition [49].
An environmental health response to geographic hot spots would also bring in the SDG # 6 on






1/4 = Need to establish burden of
illness for monitoring or research
purposes/priority setting
The geographic prevalence of S. stercoralis within Australia is essential to understand and map
the hotspots. Notification and establishing the true burden of infection will improve monitoring,
prevention and research, for assessing the effectiveness of prevention and control programs at
the local and regional levels.
Currently, there are no true disability-adjusted life years (DALYs) identified for strongyloidiasis,
mainly because of poor estimates of disease prevalence.
3 Vaccine preventability 0/4 = No vaccine available No vaccine available
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Table 1. Cont.
# Criterion Score Notes on Strongyloidiasis
4 Importance forIndigenous health 4/4 = Very high
Strongyloidiasis is endemic in the Indigenous population, affecting up to 60% of the population
in some remote communities.
Strongyloidiasis has been and continues to be an issue in the Australian Indigenous population,
causing unnecessary morbidity and mortality in all age groups [39].
Many in the Australian Indigenous population, as a result of socioeconomic conditions and
compromised/suppressed immunity due to chronic disease, are unusually susceptible to both
acute strongyloidiasis, and life-threatening disseminated and/or hyperinfective strongyloidiasis.
5 Emerging orre-emerging disease
2/4 = slowly re-emerging or
increasing incidence/prevalence
disease over the past 5 years
Strongyloidiasis has been called ‘the most neglected of Neglected Tropical Diseases’ [14].
Cases have been reported since the early 1900s. The literature shows that the prevalence of the
disease trend declined following mass drug administration (MDA) of ivermectin (2010) and
albendazole (1995) in these communities [7,13]. However, the disease has never been eliminated
and tends to reappear [5,41]. The disease has been neglected, and the real prevalence of the
disease is underestimated due to lack of disease surveillance.
Due to the unique autoinfective cycle of S. stercoralis, chronic strongyloidiasis lasts for a lifetime
if not effectively diagnosed and treated. Cases of hyperinfection and iatrogenic fatal
dissemination are predicted to increase as the infected populations age and are at a higher risk of
being immunosuppressed. Corticosteroids have been considered a factor in 65% of fatalities
from hyperinfection [50].
Another factor contributing to this emerging disease status with increasing cases of severe,
complicated strongyloidiasis, has been the lack of awareness of strongyloidiasis in medical
personnel who have been trained in Australia.
6 Communicability andpotential for outbreaks 2/4 = Medium
There is a potential for outbreaks in poor-infrastructure settings with low sanitary and hygiene
conditions, which together produce a high risk for strongyloidiasis transmission from person to
person via faecal-skin and faecal-oral routes [51].
7 Severity andsocioeconomic impacts




person) or 2/4 = medium
severity and socioeconomic
impacts in disseminated or
hyperinfective strongyloidiasis
In healthy people, chronic strongyloidiasis may have only mild, intermittent, and non-specific
symptoms. However, the autoinfection feature of this helminth and parthenogenesis,
allows single larvae reproducing within the host leading to a chronic, long-lasting disease. If not
diagnosed and treated, the disease can take a more serious form as the person becomes
immunocompromised/immunosuppressed, with an often-fatal outcome. A case fatality rate of
almost 90% has been reported [6].
Strongyloidiasis presents unnecessary cost to the health systems, as strongyloidiasis is both
preventable and treatable if diagnosed early, and in the chronic stage.
The diagnostic and treatment costs, including selective chemotherapy, targeted MDA and water,
sanitation and hygiene (WASH) have been estimated in previous research and shown to be
affordable [52,53].
It was estimated in US citizens that presumptive preventive intervention would decrease DALYs
caused by intestinal parasites, including Strongyloides, by up to 1976- saving USD 16.4 million [54].
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Table 1. Cont.
# Criterion Score Notes on Strongyloidiasis
8 Preventability
4/4 = preventive measure with
high efficacy/low side effects/high
acceptability and uptake
Adequate sanitary and hygiene conditions including safe water supply, proper toileting and
hygiene facilities would provide long term sustainable prevention and elimination of
strongyloidiasis [51]. This should be combined with health education and research to determine
the gold standard for strongyloidiasis diagnosis.
Treatment of chronic strongyloidiasis prevents hyperinfection. Currently, ivermectin is the drug
of first choice to treat human strongyloidiasis, followed by albendazole [55]. Ivermectin and
albendazole, given according to therapeutic guidelines for strongyloidiasis [41], have been
shown to eliminate the disease in 70% to 85% of those with chronic strongyloidiasis. Both drugs
have negligible side effects. Ivermectin requires only one to two administrations. Albendazole





2/4 = low to medium public concern
or political interest or
3/4 = medium to high public concern
or political interest
Strongyloidiasis is an overlooked, neglected disease [14]. However, when people are made
aware of the disease, there is high public concern. This is illustrated by a recently published
article on strongyloidiasis in ‘The Conversation’ which received a large number of responses by
the general public showing their interest and concern about the disease [56].
Closing the Gap (the health inequity gap between Indigenous and non-Indigenous Australians)
is a high priority in mainstream Australia [57]. The fact that locally-acquired infection in
Australia is almost exclusively seen in Indigenous communities should be of great public and
political concern.
Feasibility of collection
10 A case is definable
4/4 = Case has an acceptable
laboratory definition with or without
a clinical definition
A strongyloidiasis case is definable and we propose to notify strongyloidiasis by the laboratories
based on positive serology or parasitological diagnosis [58].
In disseminated and hyperinfective strongyloidiasis, faecal examination has higher sensitivity
due to large numbers of viable larvae and the patient is usually in a hospital setting at the time of
diagnosis. In immunocompetent persons, chronic strongyloidiasis might not always be detected
by microscopy due to low and irregular larval load, and serology has the highest sensitivity and
is recommended [29].
11 Data completeness islikely to be acceptable
2/4 = Data represent a proportion of
community cases with a
known undercount
Data on the prevalence of strongyloidiasis is limited.
Studies suggest that up to 60% of the population in Indigenous rural or remote communities is
infected with strongyloidiasis. A study in North Queensland found that 10% of the
non-Indigenous population has strongyloidiasis [40]. It is believed that the disease is likely to be





4/4 = No alternative surveillance
mechanisms in place. There is no surveillance mechanism available to monitor and report on strongyloidiasis.
Total score: 28–30.
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It is difficult to estimate mortality rates associated with strongyloidiasis as it is responsible for
several fatal clinical manifestations, each of which may be attributed to other causes [59]. For example,
during hyperinfective strongyloidiasis, larvae migrate from the gastrointestinal system to other organs,
transporting enteric bacteria with them. This can result in community-acquired septicaemia or
meningitis, or local sepsis, which are then registered as cause of death on death certificates, despite the
underlying cause of death being strongyloidiasis [6]. Additionally, acute strongyloidiasis can also cause
severe gastrointestinal (intestinal obstruction), or respiratory (pulmonary strongyloidiasis) disease
that can be potentially fatal if the strongyloidiasis is not diagnosed and treated [60–62].
5. Socioeconomic Impact Caused by Strongyloidiasis
Due to the chronic nature of most NTDs, their burden is usually estimated using disability-adjusted
life years (DALYs) lost. One DALY equals one year of life lost by a healthy person due to a disease.
A study in the United States of America compared the costs and benefits of no preventive intervention
and preventive intervention of 1996 people that were at risk of intestinal parasite infections, including
S. stercoralis [54]. Preventive intervention included presumptive treatment with 400 mg of albendazole
daily for five days and data was analyzed using a decision-analysis model. It was estimated that
presumptive preventive intervention against human parasites would decrease DALYs by 1976 and
save up to 16.4 million USD. While it is difficult to estimate treatment efficacy for an individual parasite
due to complexity of the tests used in this study, strongyloidiasis was shown to cause the highest
number of deaths and hospitalization costs [54]. Notably, DALYs do not describe the complete story
of harmful consequences of strongyloidiasis, such as an economic impact from productivity loses,
and social impact on individuals and the community [63]. DALYs are also not appropriate to use
when estimating the burden of strongyloidiasis due to the underestimated prevalence and in cases of
asymptomatic strongyloidiasis.
Under-diagnosis, under-treatment, and a neglected approach to this disease cause chronic
strongyloidiasis cases to develop, which is costly to the health system with expensive imaging and
investigations being undertaken before diagnosis. Currently, effective treatment of strongyloidiasis
is available and available information technology can be used to establish a notification database.
Health promotion and community engagement are also required and need to be incorporated into
public health and population health strategies, which can make a difference in disease detection and
treatment and ultimately, closing the gap.
6. Recommendation to Make Strongyloidiasis a Notifiable Disease
Notifiable disease data are collected to estimate the prevalence of the disease, identify hotspots of
infection, and determine any susceptible populations. These data will then be used by the public health
institutions and authorities to implement prevention and control measures and/or interventions at
local, regional, and national levels. Notification of the disease allows estimates of the effectiveness of
the treatment and/or control strategies that would result in a systematic evidence-based approach to
addressing this public health issue [64]. Strongyloidiasis represents a chronic, possibly widespread,
potentially debilitating, and life-threatening disease endemic in Australia, which affects Indigenous
communities and new Australian populations at a rate far in excess of the general population.
Extra-intestinal strongyloidiasis is now listed as a notifiable disease by the Centre for Disease Control
in the Northern Territory. The logical next step of national notification, and thus registration, of cases of
strongyloidiasis would allow public health authorities the critical information they need to implement
relevant prevention, control actions, and regulations.
Globally, it has been noted that strongyloidiasis is an underreported disease and information on
at-risk and affected populations is missing [15]. This review found that information on incidence is
virtually non-existent, and without this information we lack insight into ‘how often and how quickly
people are re-infected after successful treatment’, ‘how often first-time infections are sustained over a
longer period’, and knowledge of risks for infection for children and adults is missing. They argued
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for supporting longitudinal studies, especially at a community level, to address these knowledge gaps
about an important infectious disease.
There is a compelling justification for strongyloidiasis to be made notifiable in order to establish
prevalence data, identify the most severely affected regions and groups and subsequently implement
and monitor public health interventions to control this important disease. Based on this, it is
recommended that strongyloidiasis is made nationally notifiable and added to the Australian NNDL
as a matter of priority.
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